Core Viewpoint - The expectation that the global market for obesity drugs would reach $150 billion in the next decade is becoming uncertain due to falling prices for GLP-1 treatments in the U.S. [1] Group 1: Market Expectations - Wall Street's long-held expectation for the obesity drug market is now in question [1] - The anticipated market size of $150 billion may not be achievable as previously thought [1] Group 2: Pricing Trends - U.S. prices for GLP-1 treatments are experiencing a decline [1] - The price drop could significantly impact revenue projections for companies involved in obesity drug development [1]

Core Viewpoint - Novo Nordisk's stock has declined nearly 18% since the beginning of the year, raising investor concerns about its ability to compete in the obesity drug market, particularly against new entrants like Eli Lilly [1][5]. Company Overview - Novo Nordisk was the first to receive FDA approval for a GLP-1 drug for obesity, with Wegovy being launched in mid-2021, giving it a significant head start in the market [3]. - The company has faced increased competition, particularly from Eli Lilly's Zepbound, which has begun to capture market share from Wegovy [6][7]. Market Dynamics - The obesity drug market is currently valued at approximately $28 billion, with Novo Nordisk holding a 51% market share, while Eli Lilly holds the remainder [7]. - Analysts predict that the market will fragment as more obesity drugs are developed and approved, increasing competition [8]. Competitive Challenges - Novo Nordisk has experienced setbacks, including a shortage of semaglutide, which led to the FDA allowing compounding pharmacies to produce copies, creating additional competition [9]. - A clinical trial showed that Eli Lilly's Zepbound resulted in more significant weight loss compared to Wegovy, further intensifying competition [10]. - The departure of long-serving CEO Lars Fruergaard Jørgensen has also impacted investor sentiment [11]. Strategic Responses - In response to competitive pressures, Novo Nordisk acquired contract drug manufacturer Catalent for $16.5 billion to gain more control over Wegovy production [12]. - The company is actively pursuing new drug developments and has received FDA approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH) [14]. Market Projections - Future projections for the obesity drug market are optimistic, with estimates suggesting it could reach $150 billion by 2035, significantly higher than the $24 billion estimated for 2024 [15][16]. - Despite potential market fragmentation, Novo Nordisk is expected to remain a significant player due to its first-mover advantage and strong brand recognition [16].